Tagged with GI

Belgium Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is needed to drive better outcomes for their members as well as for the overall healthcare ecosystem.   Innovative Pharma: Building…

Belgium Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the key industrial investments and trends for German companies within Belux and why Belgium should be better known as an investment…

Belgium Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field – played a vital role in the development, production, and distribution of COVID-19 vaccines over the past three years. An ecosystem…

Belgium Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he helped co-found in 1999, Galapagos.   Stoffels is a heavyweight of the global pharmaceutical industry and close ally of the…

UAE Mohamed Ezz Eldin oversees Novartis operations in the UAE, Kuwait, Bahrain, Oman and Qatar. He outlines how the company’s strategy has evolved in the Gulf region following the spin-off of generics arm Sandoz and its now 100 percent focus on innovative medicines. Ezz Eldin also describes some of the key…

Hong Kong Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5” territories Singapore, Malaysia, Taiwan, Hong Kong and South Korea and is the biggest of the company’s intercontinental areas with respect…

Belgium Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the care cycle.   Patients are often left to navigate these challenges on their own, without a system in place to…

Belgium 20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets – outlines the strategic significance of the cluster to the company. Benelux is both a source and recipient of cutting-edge biopharmaceutical…

Belgium Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven and sustainable healthcare system. He calls for greater recognition from policymakers on the role that medtech can play in this…

Belgium RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters – who joined the patient advocacy field following the diagnosis of her son with a rare condition – outlines some of…

Belgium The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging Belgium’s positioning as Europe’s leading producer of vaccines -, how it is adapting and driving the green transition, and the…

Belgium Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found in 1999, Galapagos. In an exclusive conversation with PharmaBoardroom, Dr Stoffels outlines his excitement about a new CAR-T delivery model that…